ESSA Pharma Inc
EPIX1.880USD
0.000
取引時間 （ET）15分遅れの株価
83.45M時価総額
損失額直近12ヶ月PER
詳細情報 ESSA Pharma Inc 企業名
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
企業情報
企業コードEPIX
会社名ESSA Pharma Inc
上場日Feb 22, 2021
最高経営責任者「CEO」Dr. David Ross Parkinson, M.D.
従業員数35
証券種類Ordinary Share
決算期末Feb 22
本社所在地999 West Broadway, Suite 720
都市VANCOUVER
証券取引所NASDAQ Capital Market Consolidated
国Canada
郵便番号V5Z 1K5
電話番号17783310962
ウェブサイトhttps://www.essapharma.com/
企業コードEPIX
上場日Feb 22, 2021
最高経営責任者「CEO」Dr. David Ross Parkinson, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Alex Martin
Mr. Alex Martin
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
株主統計
株主統計
比率
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
種類
株主統計
比率
Hedge Fund
46.19%
Investment Advisor
13.36%
Research Firm
11.99%
Corporation
3.77%
Investment Advisor/Hedge Fund
2.45%
Individual Investor
2.24%
Venture Capital
0.05%
Other
19.93%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
91
33.44M
75.34%
-17.34M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
2023Q1
185
36.21M
82.14%
-19.98M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BVF Partners L.P.
8.75M
19.71%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.26M
5.1%
--
--
Apr 23, 2025
Tang Capital Management, LLC
4.30M
9.69%
--
--
Mar 31, 2025
BML Capital Management LLC
4.22M
9.51%
--
--
Apr 24, 2025
Morgan Stanley & Co. LLC
4.20M
9.46%
+10.76K
+0.26%
Mar 31, 2025
Opaleye Management Inc.
2.21M
4.98%
--
--
Mar 31, 2025
Pfizer Inc
1.68M
3.77%
--
--
Mar 31, 2025
Altium Capital Management LP
1.05M
2.37%
-377.63K
-26.44%
Mar 31, 2025
Berger (Franklin Milan)
784.40K
1.77%
--
--
Jan 08, 2025
BofA Global Research (US)
698.27K
1.57%
-114.04K
-14.04%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
